gebhart/patrepeval huggingface dataset:
Evaluation of Disc with Higher Track Density for Three-Dimensional Pit Selection (2007)

Get PDF Email Share Share with Facebook Tweet This Post on reddit Share with LinkedIn Add to CiteULike Add to Mendeley Add to BibSonomy Get Citation Copy Citation Text T. Shintani, H. Minemura, Y. A. and, and S. Eto, "Evaluation of Disc with Higher Track Density for Three-Dimensional Pit Selection," in Optical Data Storage, OSA Technical Digest Series (CD) (Optica Publishing Group, 2007), paper TuC1. Export Citation BibTex Endnote (RIS) HTML Plain Text Citation alert Save article
Albumin as a prognostic factor for overall survival in newly diagnosed patients with acute myeloid leukemia (AML). (2012)

6586 Background: Hypoalbuminemia (HA) is an adverse prognostic factor in multiple neoplastic diseases. Severe hypoalbuminemia (&lt;3.0 g/dl) at day +90 post allogeneic hematopoietic cell transplant (AHCT) was reported as an independent predictive variable for non-relapse mortality and overall survival (Kharfan-Dabaja, et al Biol Blood Marrow Transplant 2009; 15). We examined the prognostic value of serum albumin level prior to induction chemotherapy in patients with newly diagnosed AML. Methods: Data were collected retrospectively in newly diagnosed AML patients receiving induction chemotherapy (3+ 7 regimen). Primary objective was to examine the relationship between serum albumin at baseline and probability of achieving complete remission (CR) or incomplete remission (CRi) and overall survival (OS). The Kaplan–Meier method used to estimate median overall survival; chi-square test used for comparison of categorical variables and t-test for continuous variables. Log rank test used to compare Kaplan–Meier survival estimates between two groups. Results: Between November 2004 to July 2007, 135 patients who received 3+7 induction chemotherapy were included. Patient baseline characteristics were similar between patients with serum albumin &lt; 3.5 g/dl (HA) and those with serum albumin ≥ 3.5 g/dl (no HA) with respect to age, sex, FAB subtype, history of antecedent MDS, karyotype, and chemotherapy . In patients with HA, mean age was 60 years compared to 56.5 years in non HA group. The median OS for patients with HA was 221 days (95%CI 149.5-292.5) compared to 421 days (95%CI 236.7-605) with normal serum albumin (p&lt;0.005). (Figure-1) The CR/CRi rate was 64%% for HA and 77.6% for those with normal albumin (p=0.09). In a multivariable Cox regression analysis including age ≥ 60 years, history of MDS, karyotype, and serum albumin level at baseline; only age, karyotype and serum albumin were independent predictors of OS [Hazard ratio 0.47 (95%CI 0.31-0.71) (p&lt;0.005) for normal serum albumin group]. Conclusions: In newly diagnosed AML, we demonstrate that hypoalbuminemia &lt; 3.5 g/dl is an independent covariate for overall survival with conventional chemotherapy management. The prognostic value of low serum albumin should be validated in a prospective study.
AQP9 Expression in Glioblastoma Multiforme Tumors Is Limited to a Small Population of Astrocytic Cells and CD15+/CalB+ Leukocytes (2013)

Aquaporin-9 (AQP9) is a membrane protein channel that is permeable to a range of small solutes, including glycerol, urea and nucleobases. Expression of AQP9 in normal brain is limited, while widespread AQP9 expression has previously been reported in human glioblastoma. However, the specific cellular expression of AQP9 in glioblastoma remains unclear. In this study, we have examined microarrays to corroborate AQP9 mRNA expression in glioma. These analyses suggested that AQP9 mRNA expression in glioblastoma is primarily explained by tumor infiltration with AQP9 expressing leukocytes. Immunolabeling confirmed that within tumor regions, AQP9 was expressed in CD15(+) and Calgranulin B(+) leukocytes, but also in larger cells that morphologically resembled glioma cells. Specificity of immunoreagents was tested in recombinant cell lines, leukocyte preparations, and sections of normal human brain and liver tissue. Apparent AQP9(+) glioma cells were frequently observed in proximity to blood vessels, where brain tumor stem cells have been observed previously. A fraction of these larger AQP9 expressing cells co-expressed the differentiated astrocyte marker GFAP. AQP9 expressing glioma cells were negative for the brain tumor stem cell marker CD15, but were observed in proximity to CD15(+) glioma cells. AQP9 expression may therefore require signals of the perivascular tumor environment or alternatively it may be restricted to a population of glioma stem cell early progenitor cells.
VECSELs for microwave photonics in Radars : single-frequency, dual frequency and mode-locked low noise operation (2012)

International audience
X-Ray Image Analysis Based on Fractal Dimension (2005)

This DOI is not currently attached to any metadata records. DOIs can’t actually ever be deleted (they’re persistent), but sometimes our members create DOIs in error. We do have a process to approximate deletion which we follow only in rare cases where the DOI has been genuinely created in error, and most crucially, if the DOI has never been published anywhere online or in print and never otherwise distributed to or communicated with anyone (authors, readers, reviewers, etc.
Protein kinase C-zeta reverts v-raf transformation of NIH-3T3 cells. (1996)

We have identified protein kinase C-zeta (PKC-zeta) as a novel suppressor of neoplastic transformation caused by the v-raf oncogene. PKC-zeta overexpression drastically retards proliferation, abolishes anchorage-independent growth, and reverts the morphological transformation of v-raf-transformed NIH-3T3 cells. The molecular basis for this effect appears to be a specific induction of junB and egr-1 expression, triggered synergistically by PKC-zeta via a Raf/Mek/MAPK-independent mechanism and v-raf. junB-promoter/CAT assays revealed that PKC-zeta directly targets the junB promoter. The induction of junB and egr-1 is linked to the v-raf transformation-suppressing effect of PKC-zeta as constitutive expression of junB and egr-1 but not of c-jun also abolishes anchorage-independent growth of v-raf-transformed NIH-3T3 cells. Moreover, junB overexpression leads to a retardation of proliferation in these cells. PKC-zeta interferes with the serum inducibility of an AP-1 reporter plasmid in v-raf-transformed NIH-3T3 cells, indicating that PKC-zeta antagonizes transformation and proliferation by down-modulating AP-1 function via induction of junB. In summary, our data suggest that PKC-zeta counteracts v-raf transformation by modulating the expression of the transcription factors junB and egr-1.
Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide (2018)

The abilities of a drug delivery system to target and penetrate tumor masses are key factors in determining the system's chemotherapeutic efficacy. Here, we explored the utility of an anti-carbonic anhydrase IX (anti-CA IX) antibody and CPP33 dual-ligand modified triptolide-loaded liposomes (dl-TPL-lip) to simultaneously enhance the tumor-specific targeting and increase tumor cell penetration of TPL. In vitro, the dl-TPL-lip increased the cytotoxicity of TPL in CA IX-positive lung cancer cells, which showed tunable size (137.6 ± 0.8 nm), high-encapsulation efficiency (86.3 ± 2.6%) and sustained release. Dl-TPL-lip significantly improved the ability of liposomes to penetrate 3 D tumor spheroids and exhibited a superior inhibiting effect. Furthermore, pharmacokinetic studies in rats that received TPL liposomal formulations by endotracheal administration showed a reduced concentration of TPL (17.3%-30.6% compared to free TPL) in systemic circulation. After pulmonary administration in orthotopic lung tumor-bearing mice, dl-TPL-lip significantly enhanced TPL anti-cancer efficacy without apparent systemic toxicity. This dual-ligand modified liposomal vehicle presents a potential system for localized and targeted delivery of anti-cancer drugs to improve their efficacy.
Impairment Analysis of WDM-PON Based on Low-Cost Tunable Lasers (2016)

WDM-PON is considered for next-generation broadband backhaul and radio access networking. Among different implementation choices, we propose to utilize low-cost tunable lasers at the remote sites, together with a centralized wavelength locker. Practical implementations require a transparently added downstream signaling channel and upstream per-channel pilot tones for channel tagging and remote wavelength control. Together with some unavoidable crosstalk effects during tuning, all of these system-related items lead to impairments. To keep penalties below 1 dB, the modulation index of the signaling channel must be kept below 15%. Similar values result for the upstream pilot tones. In order to limit crosstalk, such systems require reduced launch power during wavelength tuning and can cover up to 40 km differential reach. These results confirm that WDM-PON based on low-cost lasers is a technically viable approach.
Isolation of a myoglobin molten globule by selective cobalt(III)-induced unfolding (1998)

Reaction of the Schiff-base complex [Co(acetylacetonate-ethylenediimine)(NH3)2]+ with metmyoglobin at pH 6.5 yields a partially folded protein containing six Co(III) complexes. Although half of its alpha-helical secondary structure is retained, absorption and CD spectra indicate that the tertiary structure in both B-F and AGH domains is disrupted in the partially folded protein. In analogy to proton-induced unfolding, it is likely that the loss of tertiary structure is triggered by metal-ion binding to histidines. Cobalt(III)-induced unfolding of myoglobin is unique in its selectivity (other proteins are unaffected) and in allowing the isolation of the partially folded macromolecule (the protein does not refold or aggregate upon removal of free denaturant).
Spectroscopic studies of ceruloplasmin. Electronic structures of the copper sites (1979)

ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTSpectroscopic studies of ceruloplasmin. Electronic structures of the copper sitesJohn H. Dawson, David M. Dooley, R. Clark, Philip J. Stephens, and Harry B. GrayCite this: J. Am. Chem. Soc. 1979, 101, 17, 5046–5053Publication Date (Print):August 1, 1979Publication History Published online1 May 2002Published inissue 1 August 1979https://pubs.acs.org/doi/10.1021/ja00511a040https://doi.org/10.1021/ja00511a040research-articleACS PublicationsRequest reuse permissionsArticle Views167Altmetric-Citations29LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose Get e-Alerts
63 fJ/bit heterogeneous III-V on Si modulator for the C band (2022)

Heterogeneous III-V on Si electro-optic Mach-Zehnder modulator with a p - i - n junction demonstrates V π · L of 3.4 V mm, eye diagram opening up to 12 Gb/s, and small average energy per bit of 63 fJ/bit at 12 Gb/s.
Mechanism Learning for Trading Networks (2022)

We study the problem of designing mechanisms for trading networks that satisfy four desired properties: dominant-strategy incentive compatibility, efficiency, weak budget balance (WBB), and individual rationality (IR). Although there exist mechanisms that simultaneously satisfy these properties ex post for combinatorial auctions, we prove the impossibility that such mechanisms do not exist for a broad class of trading networks. We thus propose approaches for computing and learning the mechanisms that satisfy the four properties, in a Bayesian setting, where WBB and IR, respectively, are relaxed to ex ante and interim. For computational and sample efficiency, we introduce several techniques, including game theoretical analysis to reduce the input feature space. We empirically demonstrate that the proposed approaches successfully find the mechanisms with the four properties for those trading networks where the impossibility holds ex post.
The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm (2017)

Mast cell leukemia is a rare variant of advanced systemic mastocytosis characterized by at least 20% of mast cells in a bone marrow smear. We evaluated clinical and molecular characteristics of 28 patients with (n=20, 71%) or without an associated hematologic neoplasm. <i>De novo</i> mast cell leukemia was diagnosed in 16 of 28 (57%) patients and secondary mast cell leukemia evolving from other advanced systemic mastocytosis subtypes in 12 of 28 (43%) patients, of which 7 patients progressed while on cytoreductive treatment. Median bone marrow mast cell infiltration was 65% and median serum tryptase was 520 μg/L. C-findings were identified in 26 of 28 (93%) patients. Mutations in <i>KIT</i> (D816V, n=19; D816H/Y, n=5; F522C, n=1) were detected in 25 of 28 (89%) patients and prognostically relevant additional mutations in <i>SRSF2</i>, <i>ASXL1</i> or <i>RUNX1</i> (S/A/R<sup>pos</sup>) in 13 of 25 (52%) patients. Overall response rate in 18 treatment-naïve patients was 5 of 12 (42%) on midostaurin and 1 of 6 (17%) on cladribine, and after switch 1 of 4 (25%) on midostaurin and 0 of 3 on cladribine, respectively. S/A/R<sup>pos</sup> adversely affected response to treatment and progression to secondary mast cell leukemia (n=6) or acute myeloid leukemia (n=3) while on treatment (<i>P</i><0.05). The median overall survival from mast cell leukemia diagnosis was 17 months as compared to 44 months in a control group of 124 patients with advanced systemic mastocytosis but without mast cell leukemia (<i>P</i>=0.03). In multivariate analyses, S/A/R<sup>pos</sup> remained the only independent poor prognostic variable predicting overall survival (<i>P</i>=0.007). In conclusion, the molecular signature should be determined in all patients with mast cell leukemia because of its significant clinical and prognostic relevance.
Resolution of the “No‐Reflow” Phenomenon with Intracoronary Administration of Adenosine (2000)

The “no‐reflow” phenomenon results from microcirculatory spasm and has significant hemodynamic and prognostic consequences. Adenosine is an effective microvessel vasodilator. We describe two cases of successful treatment of no‐reflow with intracoronary adenosine after failure of intracoronary calcium channel blockers . (J Interven Cardiol 2000; 13:15–18)
Fragmentation Reaction (in Mass Spectrometry) (2016)

This document contains recommendations for terminology in mass spectrometry. Development of standard terms dates back to 1974 when the IUPAC Commission on Analytical Nomenclature issued recommendations on mass spectrometry terms and definitions. In 1978, the IUPAC Commission on Molecular Structure and Spectroscopy updated and extended the recommendations and made further recommendations regarding symbols, acronyms, and abbreviations. The IUPAC Physical Chemistry Division Commission on Molecular Structure and Spectroscopy’s Subcommittee on Mass Spectroscopy revised the recommended terms in 1991 and appended terms relating to vacuum technology. Some additional terms related to tandem mass spectrometry were added in 1993 and accelerator mass spectrometry in 1994. Owing to the rapid expansion of the field in the intervening years, particularly in mass spectrometry of biomolecules, a further revision of the recommendations has become necessary. This document contains a comprehensive revision of mass spectrometry terminology that represents the current consensus of the mass spectrometry community.
Multi‐device selection scheduling in non‐identically distributed fading channels (2016)

Multiuser selection scheduling concept has been recently proposed in the literature in order to increase the multiuser diversity gain and overcome the significant feedback requirements for the opportunistic scheduling schemes. The main idea is that reducing the feedback overhead saves per‐user power that could potentially be added for the data transmission. In this work, the authors propose to integrate the principle of multiuser selection and the proportional fair scheduling scheme. This is aimed especially at power‐limited, multi‐device systems in non‐identically distributed fading channels. For the performance analysis, they derive closed‐form expressions for the outage probabilities and the average system rate of the delay‐sensitive and the delay‐tolerant systems, respectively, and compare them with the full feedback multiuser diversity schemes. The discrete rate region is analytically presented, where the maximum average system rate can be obtained by properly choosing the number of partial devices. They optimise jointly the number of partial devices and the per‐device power saving in order to maximise the average system rate under the power requirement. Through the authors’ results, they finally demonstrate that the proposed scheme leveraging the saved feedback power to add for the data transmission can outperform the full feedback multiuser diversity, in non‐identical Rayleigh fading of devices’ channels.
P501 Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders (2014)

Background: The current medical treatment options for patients with steroid-dependent, active ulcerative colitis (UC) with insufficient response or intolerance to immunosuppressants (IS) and/or biologicals are limited and not evidencebased. The clinical use of Granulocyte, Monocyte/Macrophage Adsorptive (GMA) apheresis with Adacolumn has previously indicated a potential benefit in this specific subgroup of UC patients. The present study intended to generate further clinical data to document efficacy and to identify subpopulations of this difficult-to-treat UC population that would benefit from GMA apheresis. Methods: This was an uncontrolled, open-label, multicenter trial conducted in the UK, France and Germany (ART, NCT01481142). Consecutive eligible patients (18 75 years) with steroid-dependent active UC with a Rachmilewitz (CAI) index 6 and an Endoscopic Activity Index (EAI) 4, and insufficient response or intolerance to IS and/or biologicals were included. Patients received at least 5 weekly GMA aphereses. Evaluation visits were planned at Week 12, 24 and 48. The primary endpoint was the remission rate (CAI 4) at Week 12 in the Intention-to-treat (ITT) population. Results: We report interim results from the 12 Week visit. The ITT population comprised 84 enrolled and treated patients at cutoff date. At Week 12, 33 (39.3%) subjects had achieved remission. Out of 30 patients with prior failure of IS and/or biologicals, the remission rate was 30%. Secondary efficacy parameters were clinical response defined as a reduction in CAI of 3, and steroid-free remission and response. 47 patients (55.9%) achieved response; steroid-free remission was reached by in 23% and steroid-free response was seen in 36% of the subjects. In clinical remitters, EAI dropped from 8.2 to 4.4; in clinical responders the EAI decreased from 8.6 to 5.3. Quality of life improved in parallel. The majority of Adverse Events (AEs) were of mild or moderate intensity. Six (7.1%) of 85 subjects in the Safety Population experienced serious adverse events (SAEs), all occurring during the treatment-emergent period; however, none of those SAEs was considered related to study treatment. No new safety signals were seen. Conclusions: This study describes a larger cohort of steroiddependent active UC patients with intolerance to IS and/or biologicals treated with GMA apheresis. GMA apheresis with Adacolumn showed benefit in more than 50% of patients with moderate to severe, active, steroid-dependent UC and insufficient response or intolerance to IS and/or biological agents. Further controlled studies are needed to confirm these data.
Learning Shape-from-Shading for Deformable Surfaces. (2018)

Recent years have seen the development of mature solutions for reconstructing deformable surfaces from a single image, provided that they are relatively well-textured. By contrast, recovering the 3D shape of texture-less surfaces remains an open problem, and essentially relates to Shape-from-Shading. In this paper, we introduce a data-driven approach to this problem. We introduce a general framework that can predict diverse 3D representations, such as meshes, normals, and depth maps. Our experiments show that, in contrast with the well-textured scenario, meshes a ill-suited to handle texture-less 3D reconstruction. Furthermore, we demonstrate that our approach generalizes well to unseen objects, and that it yields higher-quality reconstructions than a state-of-the-art SfS technique, particularly in terms of normal estimates. Our reconstructions accurately model the fine details of the surfaces, such as the creases of a T-Shirt worn by a person.
JRC-Names: Multilingual entity name variants and titles as Linked Data (2016)

Since 2004 the European Commission’s Joint Research Centre (JRC) has been analysing the online version of printed media in over twenty languages and has automatically recognised and compiled large amounts of named entities (persons and organisations) and their many name variants. The collected vari ants not only include standard spellings in various countries, languages and scripts, but also frequently found spelling mistakes or lesser used name forms, all occurring in real-life text (e.g. Benjamin/Binyamin/Bibi/Benyamín/Biniamin/Беньямин/بنيامين Netanyahu/Netanjahu/Nétanyahou/Netahny/Нетаньяху/نتنياهو). This entity name variant data, known as JRC-Names, has been available for public download since 2011. In this article, we report on our efforts to render JRC-Names as Linked Data (LD), using the lexicon model for ontologies lemon. Besides adhering to Semantic Web standards, this new release goes beyond the initial one in that it includes titles found next to the names, as well as date ranges when the titles and the name variants were found. It also establishes links towards existing datasets, such as DBpedia and Talk-Of-Europe. As multilingual linguistic linked dataset, JRC-Names can help bridge the gap between structured data and natural languages, thus supporting large-scale data integration, e.g. cross-lingual mapping, and web-based content processing, e.g. entity linking. JRC-Names is publicly available through the dataset catalogue of the European Union’s Open Data Portal.
Distal Triceps Tendon Repair Using an Anatomic Footprint Repair (2011)

Distal triceps tendon ruptures are an uncommon tendon injury. When surgical treatment is indicated, transosseous cruciate repair techniques have been the most commonly employed. This technique repairs the triceps to the olecranon with a narrow line of insertion, which may limit the surface area for healing and delay postoperative rehabilitation and recovery. We present an anatomic repair technique that has been shown in the laboratory both to maximally cover the distal triceps insertion footprint site and to be biomechanically stronger and more durable under cyclic load. This repair potentially permits earlier mobilization of the elbow after surgery while maintaining the integrity of the repair site.